Regulatory Science Director
Novo Nordisk, United Kingdom
Ola Oyinloye RAC, is a Regulatory Science Director at Novo Nordisk, where she drives regulatory foresight by integrating scientific and regulatory intelligence to guide enterprise decisions. Her work anticipates competitive pathways, timelines, and emerging Regulatory, Quality & Clinical trends, translating insight into actions that enhance pipeline and long-term business competitiveness.
Previously at Novo Nordisk, Ola served as a Platform Scientific Director, leading device platform and portfolio level regulatory strategy for drug device combination products and Medical Devices. In this role, she focused on deep device platform strategies internally and externally, enabling forward-looking regulatory pathways across key markets, and ensuring regulatory science was aligned with product innovation.
Prior to Novo Nordisk, Ola held regulatory leadership roles at AstraZeneca, where she led global regulatory strategy and device submissions for drug device combination products and digital health technologies. Her experience spans early development through post-approval lifecycle management, with expertise in global submissions strategies, regulatory intelligence, and cross-functional leadership.
Ola is an active contributor to the regulatory profession and currently sits on several teams in EFPIA, Biophorum, serves as Chair of the RAPS UK Local Networking Group and as a member of the RAPS RAC-Devices Committee. She is RAC-Devices certified and a published author on data-driven approaches to combination product regulatory submissions.
Alongside her Regulatory leadership, Ola is passionate about career development in Regulatory Affairs, mentoring professionals across career stages and advocating for strategic visibility, leadership readiness, and long-term career growth within the field.
RAPS Career Development Session for Students
Tuesday, May 5, 2026
15:00 - 16:00 WEST